Market Size of Global Narcolepsy Therapeutics Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.80 Billion |
| Market Size (2029) | USD 5.60 Billion |
| CAGR (2024 - 2029) | 8.04 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Narcolepsy Therapeutics Market Analysis
The Global Narcolepsy Therapeutics Market size is estimated at USD 3.80 billion in 2024, and is expected to reach USD 5.60 billion by 2029, growing at a CAGR of 8.04% during the forecast period (2024-2029).
The increasing prevalence of narcolepsy, rising narcolepsy awareness programs and services, and the presence of reimbursement policies regarding narcolepsy are significant drivers in the market. For instance, according to the journal published by the National Institute of Neurological Disorders and Strokes in January 2023, around 125,000 to 200,000 people suffered from narcolepsy in the United States in 2022. According to a January 2023 journal published by Healthline, an estimated 44.3 to 50 individuals per 100,000 in the United States were diagnosed with narcolepsy in 2022.
In addition, according to the article published by the Journal of Clinical Sleep Medicine in June 2022, an estimated 47 people per 100,000 were reported to have narcolepsy across Europe. In Germany, the incidence was estimated to be about 17.88 people per 100,000 in 2022. Such a high incidence of disorder leads to an increase in the demand and adoption of narcolepsy therapies, which is expected to drive the market's growth during the forecast period.
Market players' approval and commercialization of new drugs may also be crucial in driving market growth over the coming years. For instance, in June 2023, Avadel Pharmaceuticals PLC launched Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Thus, such strategic initiatives are expected to help the market to grow during the forecast period.
However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis may hinder the market growth during the forecast period.
Narcolepsy Therapeutics Industry Segmentation
As per the scope of the report, narcolepsy is a long-term neurological disorder involving a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Treatment usually involves lifestyle changes, medications, and behavioral strategies.
The narcolepsy therapeutics market is segmented by type, product, and geography. By type, the market is segmented into cataplexy, without cataplexy, and secondary narcolepsy. By product, the market is segmented into central nervous system stimulants, sodium oxybate, tricyclic antidepressants, and other products. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.
| By Type | |
| Narcolepsy with Cataplexy | |
| Narcolepsy without Cataplexy | |
| Secondary Narcolepsy |
| By Product | |
| Central Nervous System Stimulants | |
| Sodium Oxybate | |
| Selective Serotonin Reuptake Inhibitors | |
| Tricyclic Antidepressants | |
| Other Products |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Narcolepsy Therapeutics Market Size Summary
The narcolepsy therapeutics market is poised for significant growth, driven by factors such as the increasing prevalence of narcoleptic disorders, rising stress levels, and a growing geriatric population. The market is expected to expand due to heightened awareness of treatment options and the approval of new drugs by key players. The COVID-19 pandemic had a notable impact on market growth, as it led to decreased adoption of therapeutics and exacerbated symptoms in some regions. Despite challenges like delayed diagnosis, the market is set to benefit from advancements in central nervous system stimulants, which are crucial for improving wakefulness in patients. The development of novel therapies and regulatory approvals are central to the market's expansion.
North America is anticipated to hold a significant share of the market, supported by high healthcare spending, favorable reimbursement policies, and a strong clinical pipeline. The region's growth is further bolstered by the increasing demand for sleep disorder treatments and the effectiveness of narcolepsy therapies. The market is moderately competitive, with major players engaging in collaborations and acquisitions to drive innovation. Companies such as Avadel Pharmaceuticals, Harmony Biosciences, and Jazz Pharmaceuticals are key contributors to the market's development. The ongoing research and development efforts, along with financial support for neurological research, are expected to sustain the market's growth trajectory in the coming years.
Global Narcolepsy Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Global Prevalence of Narcolepsy
-
1.2.2 Narcolepsy Awareness Programs, Healthcare Initiatives, and Increasing Diagnosis
-
1.2.3 Regulatory Support and Presence of Reimbursement Policies Regarding Narcolepsy
-
-
1.3 Market Restraints
-
1.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs
-
1.3.2 Limited Treatment Options and High Costs Associated with Diagnosis, Treatment, and Narcolepsy Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Type
-
2.1.1 Narcolepsy with Cataplexy
-
2.1.2 Narcolepsy without Cataplexy
-
2.1.3 Secondary Narcolepsy
-
-
2.2 By Product
-
2.2.1 Central Nervous System Stimulants
-
2.2.2 Sodium Oxybate
-
2.2.3 Selective Serotonin Reuptake Inhibitors
-
2.2.4 Tricyclic Antidepressants
-
2.2.5 Other Products
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Narcolepsy Therapeutics Market Size FAQs
How big is the Global Narcolepsy Therapeutics Market?
The Global Narcolepsy Therapeutics Market size is expected to reach USD 3.80 billion in 2024 and grow at a CAGR of 8.04% to reach USD 5.60 billion by 2029.
What is the current Global Narcolepsy Therapeutics Market size?
In 2024, the Global Narcolepsy Therapeutics Market size is expected to reach USD 3.80 billion.
